TG Therapeutics, Inc. (NASDAQ:TGTX) Receives $40.80 Average Price Target from Analysts

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the five ratings firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $40.80.

Several brokerages recently weighed in on TGTX. Wall Street Zen raised TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 target price on shares of TG Therapeutics in a research report on Tuesday, March 4th.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Barclays PLC raised its position in TG Therapeutics by 83.9% in the third quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company's stock valued at $8,117,000 after purchasing an additional 158,323 shares during the period. Nisa Investment Advisors LLC raised its position in TG Therapeutics by 52.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 8,112 shares of the biopharmaceutical company's stock valued at $244,000 after purchasing an additional 2,803 shares during the period. Daymark Wealth Partners LLC raised its position in TG Therapeutics by 1.7% in the fourth quarter. Daymark Wealth Partners LLC now owns 41,500 shares of the biopharmaceutical company's stock valued at $1,249,000 after purchasing an additional 689 shares during the period. Avaii Wealth Management LLC raised its position in TG Therapeutics by 4.9% in the fourth quarter. Avaii Wealth Management LLC now owns 30,393 shares of the biopharmaceutical company's stock valued at $915,000 after purchasing an additional 1,409 shares during the period. Finally, Kingswood Wealth Advisors LLC purchased a new position in TG Therapeutics in the fourth quarter valued at about $228,000. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Trading Up 1.0%

Shares of TGTX stock traded up $0.33 during mid-day trading on Monday, hitting $34.57. 1,042,767 shares of the company's stock were exchanged, compared to its average volume of 2,983,166. TG Therapeutics has a fifty-two week low of $15.16 and a fifty-two week high of $46.48. The stock has a 50-day simple moving average of $38.13 and a two-hundred day simple moving average of $34.22. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The stock has a market cap of $5.49 billion, a price-to-earnings ratio of -345.67 and a beta of 2.21.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.16). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business had revenue of $120.86 million for the quarter, compared to analyst estimates of $117.07 million. During the same quarter last year, the business earned ($0.07) EPS. TG Therapeutics's revenue for the quarter was up 90.4% compared to the same quarter last year. Equities analysts expect that TG Therapeutics will post 0.08 EPS for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.